Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.37 |
| ▸ | ABAT | P80404 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13411815 | 0.85 | POLB (0.33) | ALDH1A1 | |
| SCHEMBL28321693 | 0.76 | NPC1 (0.42) | ALDH1A1KDM4E | |
| SCHEMBL4548451 | 0.75 | ESR1 (0.49) | HSD17B10ALDH1A1TYRKDM4E | |
| SCHEMBL5020203 | 0.75 | POLB (0.48) | ALDH1A1 | |
| SCHEMBL5020178 | 0.75 | ASIC3 (0.48) | HSD17B10BRD4ALDH1A1KDM4E | |
| SCHEMBL5020183 | 0.75 | MEN1 (0.46) | CYP2A6ALDH1A1 | |
| SCHEMBL17283676 | 0.75 | SCN4A (0.43) | ALDH1A1 | |
| SCHEMBL1187135 | 0.75 | RPS6KA3 (0.42) | — | |
| SCHEMBL5020182 | 0.75 | SMN1; SMN2 (0.46) | HSD17B10ALDH1A1KDM4E | |
| SCHEMBL5020208 | 0.75 | METAP2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383634-B2 | Methods of treatment using heteroaryl compounds and compositions thereof | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110224217-A1 | METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF | SIGNAL PHARMACEUTICALS, LLC | 2011-09-15 | — | — | US | disclosed |
| US-7968556-B2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-06-28 | — | — | US | disclosed |
| CN-101679432-A | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | SIGNAL PHARM LLC | 2010-03-24 | — | — | CN | disclosed |
| EP-2078018-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-02-12 | — | — | US | disclosed |
| WO-2008051494-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224217-A1 | METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF | JAK2, CHEK2, PHKG1 | CYP2A6 1657/4885HSD17B10 1113/4885ALDH5A1 1974/4885 |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, SRC | CYP2A6 1331/4885HSD17B10 1007/4885ALDH5A1 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.